Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (67616)	9/13/1999 12:29:00 PM
From: bob s	Read Replies (1) \| Respond to of 132070

MB-Would you comment on the CEFs-i e which regions have the most/least appeal-Latin America/Asia excluding Japan etc Thanks in advance Bob

To: Knighty Tin who wrote (67616)	9/13/1999 1:51:00 PM
From: Greg Jung	Read Replies (1) \| Respond to of 132070

Mike please expand a bit on Incyte. I looked at them when they took the Big dive after last earnings, I didn't notice they had a chip. Are these chips just now coming into production at Affimetrix and Incyte, and is that what the hoopla on the share prices has been? Also in the same general topic, it looks to me like Celera is doing exactly what it promised a year ago or so, that is to kick HGSI, NIH's collective butt. And the the income/sales ratio is a trifle, only about -4 or so. Despite a purported "qualitative" difference in data collected, having a 2-?? year advantage over the NIH dataset could render that obsolete. Watta ya think.